PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452 PDF Version PhaseBio to receive up to $120 million in development...

News Release Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor...

Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications Apellis to receive up to $120 million in...

Watch how SFJ Pharmaceutical's innovative business model accelerates the process that gets innovative drugs to patients in need.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Background:...

Eisai Launches Anticancer Agent Lenvima® (Lenvatinib Mesylate) In United Kingdom Indicated For Advanced Thyroid Cancer Refractory To Radioactive Iodine Eisai...

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Approval Supported...

Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group Agreement enables Merck KGaA, Darmstadt,...

PFIZER RECEIVES FDA APPROVAL FOR MYLOTARG™ (GEMTUZUMAB OZOGAMICIN) ONLY APPROVED ANTIBODY-DRUG CONJUGATE FOR NEWLY DIAGNOSED AND RELAPSED OR REFRACTORY CD33-POSITIVE...

PFIZER RECEIVES U.S. FDA APPROVAL FOR BESPONSA® (INOTUZUMAB OZOGAMICIN) August 17, 2017 BESPONSA is the first and only CD22-directed antibody-drug...